December 23, 2020
Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
November 24, 2020
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
November 19, 2020
Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study
November 12, 2020
Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
November 10, 2020
Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference
November 2, 2020
Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results
October 27, 2020
Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results
October 7, 2020
Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
September 8, 2020
Urovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment Conference
August 13, 2020
Urovant Sciences Reports Fiscal First Quarter 2020 Results
August 6, 2020
Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results
June 18, 2020
Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results
June 18, 2020
Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
June 11, 2020
Urovant Sciences to Report Fiscal Year and Fourth Quarter 2019 Results
June 2, 2020
Urovant Sciences Appoints Walt Johnston as Senior Vice President of Commercial, Kenton Stewart as Senior Vice President of Market Access
May 27, 2020
Urovant Sciences Appoints James Hindman to Board of Directors
May 26, 2020
Urovant Sciences to Present at the Jefferies Virtual Healthcare Conference
May 14, 2020
Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting
March 23, 2020
Urovant Sciences Appoints James Robinson as President and Chief Executive Officer
March 5, 2020
Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder
March 2, 2020
Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology
February 25, 2020
Urovant Sciences to Present at Cowen and Company’s 40th Annual Health Care Conference
February 13, 2020
Urovant Sciences Reports 2019 Third Fiscal Quarter Financial Results
February 6, 2020
Urovant Sciences to Report 2019 Third Fiscal Quarter Financial Results
February 4, 2020
Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Overactive Bladder
January 17, 2020
Urovant Sciences to Ring the Nasdaq Stock Market Opening Bell
January 8, 2020
Urovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference